The Centers for Disease Control and Prevention defines preconceptional care as “a set of interventions that aim to identify and modify biomedical, behavioral, and social risks to a woman’s health or pregnancy outcome through prevention and management” (Johnson, 2006). The following goals were established for advancing preconceptional care:
1. Improve knowledge, attitudes, and behaviors of men and women related to preconceptional health.
2. Assure that all women of childbearing age receive preconceptional care services—including evidence-based risk screening, health promotion, and interventions—that will enable them to enter pregnancy in optimal health.
3. Reduce risks indicated by a previous adverse pregnancy outcome through interconceptional interventions to prevent or minimize recurrent adverse outcomes.
4. Reduce the disparities in adverse pregnancy outcomes.
The American College of Obstetricians and Gynecologists (2012c) also has reaffirmed the importance of preconceptional and interpregnancy care.
To illustrate potentially modifiable conditions, data that describe the health status of women who gave birth to liveborn infants in the United States in 2004 are reviewed. Table 8-1 demonstrates the high prevalence of many conditions that may be amenable to intervention during the preconceptional and interpregnancy periods (D’Angelo, 2007). To be successful, however, preventative strategies that mitigate these potential pregnancy risks must be provided before conception. By the time most women realize they are pregnant—usually 1 to 2 weeks after the first missed period—the embryo has already begun to form. Thus, many prevention strategies—for example, folic acid to prevent neural-tube defects—will be ineffective if initiated at this time. Importantly, up to half of all pregnancies are unplanned, and often these are at greatest risk (Cheng, 2009).
TABLE 8-1. Prevalence of Prepregnancy Maternal Behaviors, Experiences, Health Conditions, and Previous Poor Birth Outcomes in the United States in 2004
Few randomized trials evaluate preconceptional counseling efficacy, in part because withholding such counseling would be unethical. Also, because pregnancy outcomes are dependent on the interaction of various maternal, fetal, and environmental factors, it is often difficult to ascribe salutary outcomes to a specific intervention (Moos, 2004). There are, however, prospective observational and case-control studies that demonstrate the successes of preconceptional counseling. Moos and coworkers (1996) assessed the effectiveness of a preconceptional counseling program administered during routine health care provision to reduce unintended pregnancies. The 456 counseled women had a 50-percent greater likelihood of subsequent pregnancies that they considered “intended” compared with 309 uncounseled women. Moreover, the counseled group had a 65-percent higher rate of intended pregnancy compared with women who had no health care before pregnancy. There are interesting ethical aspects of paternal lifestyle modification reviewed by van der Zee and associates (2013).
Gynecologists, internists, family practitioners, and pediatricians have the best opportunity to provide preventive counseling during periodic health maintenance examinations. The occasion of a negative pregnancy test is also an excellent time for education. Jack and colleagues (1995) administered a comprehensive preconceptional risk survey to 136 such women, and almost 95 percent reported at least one problem that could affect a future pregnancy. These included medical or reproductive problems—52 percent, family history of genetic disease—50 percent, increased risk of human immunodeficiency virus infection—30 percent, increased risk of hepatitis B and illegal substance abuse—25 percent, alcohol use—17 percent, and nutritional risks—54 percent. Counselors should be knowledgeable regarding relevant medical diseases, prior surgery, reproductive disorders, or genetic conditions and must be able to interpret data and recommendations provided by other specialists. If the practitioner is uncomfortable providing guidance, the woman or couple should be referred to an appropriate counselor.
Women presenting specifically for preconceptional evaluation should be advised that information collection may be time consuming depending on the number and complexity of factors that require assessment. The intake evaluation includes a thorough review of the medical, obstetrical, social, and family histories. Useful information is more likely to be obtained by asking specific questions regarding each history and each family member than by asking general, open-ended questions. Some important information can be obtained by questionnaires that address these topics. Answers are reviewed with the couple to ensure appropriate follow-up, including obtaining relevant medical records.
With specific medical conditions, general points include how pregnancy will affect maternal health and how a high-risk condition might affect the fetus. Afterward, advice for improving outcome is provided. Detailed preconceptional information regarding a few conditions is found in the next sections as well as in the other topic-specific chapters of this text.
Because maternal and fetal pathology associated with hyperglycemia is well known, diabetes is the prototype of a condition for which preconceptional counseling is beneficial. Diabetes-associated risks to both mother and fetus are discussed in detail in Chapter 57 (p. 1125). Many of these complications can be avoided if glucose control is optimized before conception. The American College of Obstetricians and Gynecologists (2012b) has concluded that preconceptional counseling for women with pregestational diabetes is both beneficial and cost-effective and should be encouraged. The American Diabetes Association has promulgated consensus recommendations for preconceptional care for diabetic women (Kitzmiller, 2008). These guidelines advise that a thorough inventory of disease duration and related complications be obtained and clinical and laboratory examination for end-organ damage be completed. Perhaps most importantly, they encourage a preconceptional goal of the lowest hemoglobin A1c level possible without undue hypoglycemic risk to the mother. In addition to assessing diabetic control during the preceding 6 weeks, hemoglobin A1c measurement can also be used to compute risks for major anomalies (Fig. 8-1). Although these data are from women with severe overt diabetes, the incidence of fetal anomalies in women who have gestational diabetes with fasting hyperglycemia is increased fourfold compared with that in normal women (Sheffield, 2002).
FIGURE 8-1 Relationship between first-trimester glycosylated hemoglobin values and risk for major congenital malformations in 320 women with insulin-dependent diabetes. (Data from Kitzmiller, 1991.)
Such counseling has been shown to be effective. In one review, Leguizamón and associates (2007) identified 12 studies that included more than 3200 pregnancies in women with insulin-dependent diabetes. Of the 1618 women without preconceptional counseling, 8.3 percent had a fetus with a major congenital anomaly, and this compared with a rate of 2.7 percent in the 1599 women who did have counseling. Tripathi and coworkers (2010) compared outcomes in 588 women with pregestational diabetes in whom about half had preconceptional counseling. Those women who received counseling had improved glycemic control before pregnancy and in the first trimester, had higher folate intake rates preconceptionally, and experienced lower rates of adverse outcomes—defined as a perinatal death or major congenital anomaly. These cited benefits are accompanied by reduced health-care costs in diabetic women. From their review, Reece and Homko (2007) found that each $1 expended for a preconceptional care program saved between $1.86 and $5.19 in averted medical costs. Despite such benefits, the proportion of diabetic women receiving preconceptional care is suboptimal. In their study of approximately 300 diabetic women in a managed-care plan, Kim and colleagues (2005) found that only about half had preconceptional counseling. Counseling rates are undoubtedly much lower among uninsured and indigent women.
Women who have epilepsy have an undisputed two- to threefold risk of having infants with structural anomalies compared with unaffected women (Wide, 2004). Some early reports indicated that epilepsy conferred an increased a priori risk for congenital malformations that was independent of any effects of anticonvulsant treatment. Although more recent publications have largely failed to confirm this increased risk in untreated women, it is difficult to refute entirely because women who are controlled without medication generally have less severe disease (Cassina, 2013). Fried and associates (2004) conducted a metaanalysis of studies comparing epileptic women, both treated and untreated, with controls. In this study, increased malformation rates could only be demonstrated in the offspring of women who had been exposed to anticonvulsant therapy. Veiby and coworkers (2009) used the Medical Birth Registry of Norway to compare pregnancy outcomes in 2861 deliveries by epileptic women with 369,267 control deliveries. They identified an increased malformation risk only in women who were exposed to valproic acid (5.6 percent) and polytherapy (6.1 percent). Untreated women had anomaly rates that were similar to those of nonepileptic controls.
Ideally, seizure control is optimized preconceptionally. Vajda and colleagues (2008) reported data from the Australian Register of Antiepileptic Drugs in Pregnancy. The risk of seizures during pregnancy was decreased by 50 to 70 percent if there were no seizures in the year preceding pregnancy. There were no further advantages that accrued if the seizure-free period exceeded a year.
Efforts should attempt to achieve seizure control with monotherapy and with medications considered less teratogenic (Aguglia, 2009; Tomson, 2009). As discussed in detail in Chapter 60 (p. 1190) and shown in Table 8-2, some one-drug regimens are more teratogenic than others. Valproic acid, in particular, should be avoided if possible, as this medication has consistently been associated with a greater risk for major congenital malformations than other antiepileptic drugs (Jentink, 2010). According to Jeha and Morris (2005), the American Academy of Neurology recommends consideration of antiseizure medication discontinuation before pregnancy in suitable candidates. These are women who satisfy the following criteria: have been seizure-free for 2 to 5 years, display a single seizure type, have a normal neurological examination and normal intelligence, and show electroencephalogram results that have normalized with treatment.
TABLE 8-2. First-Trimester Antiepileptic Monotherapy and the Associated Congenital Malformation Risk
Epileptic women should be advised to take supplemental folic acid. However, it is not entirely clear that folate supplementation reduces the fetal malformation risk in pregnant women taking anticonvulsant therapy. In one case-control study, Kjær and associates (2008) reported that the congenital abnormality risk was reduced by maternal folate supplementation in fetuses exposed to carbamazepine, phenobarbital, phenytoin, and primidone. Conversely, from the United Kingdom Epilepsy and Pregnancy Register, Morrow and coworkers (2009) compared fetal outcomes of women who received preconceptional folic acid with those who did not receive it until later in pregnancy or not at all. In this study, a paradoxical increase in the number of major congenital malformations was observed in the group who received preconceptional folate. These investigators concluded that folate metabolism may be only a part of the mechanism by which malformations are induced in women taking these medications.
Preconceptional counseling includes assessment of immunity against common pathogens. Also, depending on health status, travel plans, and time of year, other immunizations may be indicated as discussed in Chapter 9 (Table 9-9, p. 186). Vaccines that contain toxoids—for example, tetanus, or that consist of killed bacteria or viruses—such as influenza, pneumococcus, hepatitis B, meningococcus, and rabies—have not been associated with adverse fetal outcomes and are not contraindicated preconceptionally or during pregnancy. Conversely, live-virus vaccines—including varicella-zoster, measles, mumps, rubella, polio, chickenpox, and yellow fever—are not recommended during pregnancy. Moreover, 1 month or longer should ideally pass between vaccination and conception attempts. That said, inadvertent administration of measles, mumps, rubella (MMR) or varicella vaccines during pregnancy should not generally be considered indications for pregnancy termination. Most reports indicate that the fetal risk is only theoretical. Immunization to smallpox, anthrax, and other bioterrorist diseases should be discussed if clinically appropriate (Chap. 64, p. 1258). Based on their study of approximately 300 women who received smallpox vaccination near the time of conception, Ryan and colleagues (2008) found that rates of pregnancy loss, preterm birth, and birth defects were not higher than expected.
The Centers for Disease Control and Prevention (2013) estimate that 3 percent of neonates born each year in the United States will have at least one birth defect. Importantly, such defects are the leading cause of infant mortality and account for 20 percent of deaths. The benefits of preconceptional counseling usually are measured by comparing the incidence of new cases before and after initiation of a counseling program. Congenital conditions that clearly benefit from patient education include neural-tube defects, phenylketonuria, thalassemias, and other genetic diseases more common in individuals of Eastern European Jewish descent.
Pedigree construction using the symbols shown in Figure 8-2 is the most thorough method for obtaining a family history as a part of genetic screening. The health and reproductive status of each “blood relative” should be individually reviewed for medical illnesses, mental retardation, birth defects, infertility, and pregnancy loss. Certain racial, ethnic, or religious backgrounds may indicate increased risk for specific recessive disorders.
FIGURE 8-2 Symbols used for pedigree construction. (Redrawn from Thompson, 1991.)
Although most women can provide some information regarding their history, their understanding may be limited. For example, several studies have shown that pregnant women often fail to report a birth defect in the family or they report it incorrectly. Thus, any disclosed defect or genetic disease should be confirmed by reviewing pertinent medical records or by contacting affected relatives for additional information.
The incidence of neural-tube defects (NTDs) is 0.9 per 1000 live births, and they are second only to cardiac anomalies as the most frequent structural fetal malformation (Chap. 14, p. 283). Some NTDs, as well as congenital heart defects, are associated with specific mutations. One example is the 677C → T substitution in the gene that encodes methylene tetrahydrofolate reductase. For this and similar gene defects, the trial conducted by the Medical Research Council Vitamin Study Research Group (1991) showed that preconceptional folic acid therapy significantly reduced the risk for a recurrent NTD by 72 percent. More importantly, because more than 90 percent of infants with NTDs are born to women at low risk, Czeizel and Dudas (1992) showed that supplementation reduced the a priori risk of a first NTD occurrence. It is currently recommended, therefore, that all women who may become pregnant take 400 to 800 μg of folic acid orally daily before conception and through the first trimester (U.S Preventive Services Task Force, 2009). Folate fortification of cereal grains has been mandatory in the United States since 1998, and this practice has also resulted in decreased neural-tube defect rates (Mills, 2004). Despite the demonstrated benefits of folate supplementation, only half of women have taken folic acid supplementation periconceptionally (de Jong-van den Berg, 2005; Goldberg, 2006). The strongest predictor of use appears to be consultation with a health-care provider before conception.
This inherited phenylalanine metabolism defect exemplifies diseases in which the fetus may not be at risk to inherit the disorder but may be damaged by maternal disease. Specifically, mothers with phenylketonuria (PKU) who eat an unrestricted diet have abnormally high blood phenylalanine levels. This amino acid readily crosses the placenta and can damage developing fetal organs, especially neural and cardiac tissues (Table 8-3). With appropriate preconceptional counseling and adherence to a phenylalanine-restricted diet before pregnancy, the incidence of fetal malformations is dramatically reduced (Guttler, 1990; Hoeks, 2009; Koch, 1990). It is recommended, therefore, that the phenylalanine concentration be normalized 3 months before conception and that these levels be maintained throughout pregnancy (American College of Obstetricians and Gynecologists, 2009b).
TABLE 8-3. Frequency of Complications in the Offspring of Women with Untreated Phenylketonuriaa (Blood Phenylalanine > 1200 μmol/L)
These disorders of globin-chain synthesis are the most common single-gene disorders worldwide. As many as 200 million people carry a gene for one of these hemoglobinopathies, and hundreds of mutations are known to cause thalassemia syndromes (Chap. 56, p. 1112). In endemic areas such as Mediterranean and Southeast Asian countries, counseling and other prevention strategies have reduced the incidence of new cases by up to 80 percent (Angastiniotis, 1998). For example, more than 25,000 students of Mediterranean origin were counseled and tested for β-thalassemia during a 20-year period (Mitchell, 1996). Within a few years of program initiation, all high-risk couples who requested prenatal diagnosis had completed the program, and remarkably, there were no affected children born during this period.
The American College of Obstetricians and Gynecologists (2013b) recommends that individuals of high-risk ancestry be offered carrier screening to allow them informed decision making regarding reproduction and prenatal diagnosis. One method—preimplantation genetic diagnosis, which is discussed in Chapter 14 (p. 301)—is available for patients at risk for certain thalassemia syndromes (Chen, 2008; Kuliev, 2011).
Individuals of Eastern European Jewish Descent
Most individuals of Jewish ancestry in North America are descended from Ashkenazi Jewish communities and are at increased risk for having offspring with one of several autosomal recessive disorders. These include Tay-Sachs disease, Gaucher disease, cystic fibrosis, Canavan disease, familial dysautonomia, mucolipidosis IV, Niemann-Pick disease type A, Fanconi anemia group C, and Bloom syndrome. The American College of Obstetricians and Gynecologists (2009c) recommends preconceptional counseling and screening for these in this population. Carrier frequency and features of these conditions are discussed in Chapter 14 (Table 14-11, p. 298).
During preconceptional screening, information should be sought regarding infertility; abnormal pregnancy outcomes that may include miscarriage, ectopic pregnancy, and recurrent pregnancy loss; and obstetrical complications such as preeclampsia, placental abruption, and preterm delivery (Stubblefield, 2008). As discussed in Chapter 35 (p. 664), details involving a prior stillbirth are especially important. For example, Korteweg and associates (2008) identified chromosomal abnormalities in 13 percent of stillborns who underwent karyotyping. More recently, Reddy and colleagues (2012) confirmed that chromosomal microarray analysis yielded better detection of genetic abnormalities than did standard karyotyping, primarily because nonviable tissue can be used for the analysis. Identification of a genetic abnormality in stillborns can help determine the recurrence risk and aid in the preconceptional or prenatal management in subsequent pregnancies.
Women at both ends of the reproductive-age spectrum have unique outcomes to be considered. First, according to the Centers for Disease Control and Prevention, in 2010, 3.4 percent of births in the United States were in women between the ages of 15 and 19 years (Martin, 2012). This rate represents a historical low in the United States for teenage births with a 45-percent decline since 1991. That said, adolescents are at increased risk for anemia, preterm delivery, and preeclampsia compared with women aged 20 to 35 years (Usta, 2008). The incidence of sexually transmitted diseases—common in adolescents—is even higher during pregnancy (Niccolai, 2003). Unfortunately, because most of their pregnancies are unplanned, adolescents rarely seek preconceptional counseling.
In contrast, conceptions after age 35 currently comprise approximately 15 percent of pregnancies in the United States (Martin, 2012). The older woman is more likely to request preconceptional counseling, either because she has postponed pregnancy and now wishes to optimize her outcome, or because she plans to undergo infertility treatment. Some studies—including data from Parkland Hospital presented in Figure 8-3—indicate that after age 35, there is an increased risk for obstetrical complications as well as perinatal morbidity and mortality (Cunningham, 1995; Huang, 2008). The older woman who has a chronic illness or who is in poor physical condition usually has readily apparent risks. For the physically fit woman without medical problems, however, the risks are much lower than previously reported.
FIGURE 8-3 Incidence of selected pregnancy complications in relation to maternal age among 295,667 women delivered at Parkland Hospital, 1988–2012. (Courtesy of Dr. Donald McIntire.)
Overall, the maternal mortality rate is higher in women aged 35 and older (Chap. 1, p. 5). Compared with women in their 20s, women aged 35 to 39 are 2.5 times more likely and women aged 40 or older are 5.3 times more likely to suffer pregnancy-related mortality (Geller, 2006). According to Buehler and coworkers (1986), improved medical care may ameliorate these risks. They reviewed maternal deaths in the United States from 1974 through 1982. Through 1978, older women had a fivefold increased relative risk of maternal death compared with that of younger women. By 1982, however, the mortality rates for older women had decreased by 50 percent.
For the fetus, maternal age-related risks primarily stem from: (1) indicated preterm delivery for maternal complications such as hypertension and diabetes, (2) spontaneous preterm birth, (3) fetal-growth disorders related to chronic maternal disease or multifetal gestation, (4) fetal aneuploidy, and (5) pregnancies resulting from assisted reproductive technology.
Assisted Reproductive Technologies
Recall that older women have subfertility problems. And although the incidence of dizygotic twinning increases with maternal age, the more important cause of multifetal gestation in older women follows the use of assisted reproductive technology (ART) and ovulation induction. Indeed, according to the Centers for Disease Control and Prevention, 40 percent of all multifetal gestations in the United States in 2005 were conceived with the use of ART (Martin, 2010). Multifetal pregnancies account for much of the morbidity and mortality from preterm delivery. Other obstetrical morbidities, such as placenta previa and abruption, are also risks associated with ART (Fong, 2014).
During the past decade, experience has accrued that links ART to increased major congenital malformation rates. Davies and colleagues (2012) reported that of 308,974 births in South Australia, 8.3 percent of infants conceived by ART had major birth defects. In this analysis, after adjustment for maternal age and other risk factors, intracytoplasmic injection continued to be associated with a significantly increased risk for malformations, but in vitro fertilization did not.
Although there is an increased incidence of genetic diseases in offspring caused by new autosomal-dominant mutations in older men, the incidence is still low (Chap. 13, p. 270). Accordingly, targeted sonographic examination performed solely for advanced maternal or paternal age is controversial.
Recreational Drugs and Smoking
Fetal risks associated with alcohol, marijuana, cocaine, amphetamines, and heroin are discussed in Chapter 12 (p. 253). The first step in preventing drug-related fetal risk is for the woman to honestly assess her use. Questioning should be nonjudgmental. Screening for at-risk drinking can be accomplished using a number of validated tools, like the well-studied TACE questions (American College of Obstetricians and Gynecologists, 2013a). This is a series of four questions concerning tolerance to alcohol, being annoyed by comments about their drinking, attempts to cut down, and a history of drinking early in the morning—the eye opener.
In a Canadian study of more than 1000 postpartum patients, Tough and coworkers (2006) found that a high percentage of women reported alcohol use concurrent with conceptional attempts. Specifically, nearly half of those planning for pregnancy reported a mean of 2.2 drinks daily during early gestation before they recognized their pregnancy. Of note, Bailey and associates (2008) found that rates of binge drinking and marijuana use by men were unaffected by their partner’s pregnancy. The frequency and pattern of such behaviors clearly underscore the opportunity for preconceptional counseling.
In 2005, approximately 14 percent of women giving birth in the United States smoked cigarettes (Tong, 2009). This practice has been consistently associated with numerous adverse perinatal outcomes. These risks are largely mitigated by cessation before pregnancy, highlighting the importance of screening for tobacco use in the preconceptional period and during prenatal care as outlined in Chapter 9 (p. 172).
Contact with environmental substances is inescapable. Thus, it is fortunate that only a few agents have been shown to cause adverse pregnancy outcomes (Windham, 2008). Exposures to infectious diseases have myriad deleterious effects, and these are detailed in Chapters 64 and 65 (p. 1239). Likewise, contact with some chemicals may impart significant maternal and fetal risks. As discussed in Chapters 8 and 12 (pp. 183 and 250), excess exposure to methyl mercury or lead is associated with neurodevelopmental disorders.
In the past, some concerns were raised over common everyday exposure to electromagnetic fields such as emanated by high-voltage power lines, electric blankets, microwave ovens, and cellular phones. Fortunately, there is no human or animal evidence that any of these cause adverse fetal effects (O’Connor, 1999; Robert, 1999). The effects of electrical shock are discussed in Chapter 47 (p. 956).
Pica is the craving for and consuming of ice, laundry starch, clay, dirt, or other nonfood items. It should be discouraged due to its inherent replacement of healthful food with nutritionally empty products (Chap. 9, p. 188). In some cases, it may represent an unusual physiological response to iron deficiency (Federman, 1997). Many vegetarian diets are protein deficient but can be corrected by increasing egg and cheese consumption. Anorexia and bulimiaincrease maternal risks of nutritional deficiencies, electrolyte disturbances, cardiac arrhythmias, and gastrointestinal pathology (Becker, 1999). With these, pregnancy-related complications include greater risks of low birthweight, smaller head circumference, microcephaly, and small for gestational age (Kouba, 2005).
In contrast, obesity is linked with several maternal complications. As discussed in Chapter 48 (p. 965), these include hypertension, preeclampsia, gestational diabetes, labor abnormalities, cesarean delivery, and operative complications (American College of Obstetricians and Gynecologists, 2013c). Obesity also appears to be associated with a range of structural fetal anomalies (Stothard, 2009). By comparing changes in prepregnancy body mass index (BMI), Villamor and Cnattingius (2006) found that modest increases in BMI before pregnancy could result in perinatal complications, even if a woman does not become overweight.
Conditioned pregnant women usually can continue to exercise throughout gestation (American College of Obstetricians and Gynecologists, 2009a). As discussed in Chapter 9 (p. 182), there are no data to suggest that exercise is harmful during pregnancy. One caveat is that as pregnancy progresses, balance problems and joint relaxation may predispose to orthopedic injury. A woman should be advised not to exercise to exhaustion, and she should augment heat dissipation and fluid replacement. Further avoidances include supine positions, activities requiring good balance, and extreme weather conditions.
Intimate Partner Violence
Pregnancy can exacerbate interpersonal problems and is a time of increased risk from an abusive partner. According to the American College of Obstetricians and Gynecologists (2012a), approximately 324,000 pregnant women are abused each year. As discussed in Chapter 47 (p. 951), intimate partner violence has been associated with an increased risk for several pregnancy-related complications, including hypertension, vaginal bleeding, hyperemesis, preterm delivery, and low-birthweight infants (Silverman, 2006). Because domestic violence can escalate during pregnancy, even to the point of homicide, the preconceptional period provides an ideal time for screening, and if indicated, intervention (Cheng, 2010). As outlined in Chapter 9 (p. 174), the American College of Obstetricians and Gynecologists (2012a) has provided recommendations and resources for screening both pregnant and nonpregnant women for domestic violence.
Certain laboratory tests may be helpful in assessing the risk for and preventing some complications during pregnancy. These include basic tests that are usually performed during prenatal care and are discussed in Chapter 9. More specific tests may assist evaluation of women with certain chronic medical diseases. Examples of some, but certainly not all, chronic diseases that ideally would be assessed before conception are highlighted in Table 8-4. With several of these, optimizing maternal condition before conception will improve pregnancy outcomes. Cox and coworkers (1992) reviewed pregnancy outcomes in 1075 high-risk women who received such evaluation. They reported that the 240 women with hypertension, asthma, or renal, thyroid, or cardiac disease had better outcomes compared with the outcomes from their previous pregnancies.
TABLE 8-4. Selected Preconceptional Counseling Topics
Aguglia U, Barboni G, Battino D, et al: Italian consensus conference on epilepsy and pregnancy, labor and puerperium. Epilepsia 50:7, 2009
American College of Obstetricians and Gynecologists: Exercise during pregnancy and the postpartum period. Committee Opinion No. 267, January 2002, Reaffirmed 2009a
American College of Obstetricians and Gynecologists: Maternal phenylketonuria. Committee Opinion No. 449, December 2009b
American College of Obstetricians and Gynecologists: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Committee Opinion No. 442, October 2009c
American College of Obstetricians and Gynecologists: Intimate partner violence. Committee Opinion No. 518, 2012a
American College of Obstetricians and Gynecologists: Pregestational diabetes mellitus. Practice Bulletin No. 60, March 2005, Reaffirmed 2012b
American College of Obstetricians and Gynecologists: The importance of preconception care in the continuum of women’s health care. Committee Opinion No. 313, September 2005, Reaffirmed 2012c
American College of Obstetricians and Gynecologists: At-risk drinking and alcohol dependence: obstetric and gynecologic implications. Committee Opinion No. 496, August 2011, Reaffirmed 2013a
American College of Obstetricians and Gynecologists: Hemoglobinopathies in pregnancy. Practice Bulletin No. 78, January 2007, Reaffirmed 2013b
American College of Obstetricians and Gynecologists: Obesity in pregnancy.
Committee Opinion No. 549, January 2013c
Angastiniotis M, Modell B: Global epidemiology of hemoglobin disorders. Ann NY Acad Sci 850:251, 1998
Bailey JA, Hill KG, Hawkins JD, et al: Men’s and women’s patterns of substance use around pregnancy. Birth 35:1, 2008
Becker AE, Grinspoon SK, Klibanski A, et al: Eating disorders. N Engl J Med 340:14, 1999
Buehler JW, Kaunitz AM, Hogue CJR, et al: Maternal mortality in women aged 35 years or older: United States. JAMA 255:53, 1986
Cassina M, Dilaghi A, Di Gianantonio E, et al: Pregnancy outcome in women exposed to antiepileptic drugs: teratogenic role of maternal epilepsy and its pharmacologic treatment. Reprod Toxicol 39:50, 2013
Centers for Disease Control and Prevention: Birth defects. 2013. Available at: http://www.cdc.gov/ncbddd/birthdefects/data.html. Accessed June 16, 2013
Chen SU, Su YN, Fang MY, et al: PGD of beta-thalassaemia and HLA haplotypes using OminiPlex whole genome amplification. Reprod Biomed Online 17:699, 2008
Cheng D, Horon IL: Intimate-partner homicide among pregnant and postpartum women. Obstet Gynecol 115(6):1181, 2010
Cheng D, Schwarz EB, Douglas E, et al: Unintended pregnancy and associated maternal preconception, prenatal and postpartum behaviors. Contraception 79:194, 2009
Cox M, Whittle MJ, Byrne A, et al: Prepregnancy counseling: experience from 1075 cases. Br J Obstet Gynaecol 99:873, 1992
Cunningham FG, Leveno KJ: Childbearing among older women—the message is cautiously optimistic. N Engl J Med 333:953, 1995
Czeizel AE, Dudas I: Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327:1832, 1992
D’Angelo D, Williams L, Morrow B, et al: Preconception and interconception health status of women who recently gave birth to a live-born infant—Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 26 reporting areas, 2004. MMWR 56(10):1, 2007
Davies MJ, Moore VM, Willson KJ, et al: Reproductive technologies and the risk of birth defects. N Engl J Med 366(19):1803, 2012
de Jong-van den Berg LTW, Hernandez-Diaz S, Werler MM, et al: Trends and predictors of folic acid awareness and periconceptional use in pregnant women. Am J Obstet Gynecol 192:121, 2005
Federman DG, Kirsner RS, Federman GS: Pica: are you hungry for the facts? Conn Med 61:207, 1997
Fong A, Lovell S, Rad, S, et al: Obstetrical complications of deliveries conceived by assisted reproductive technology in California. Abstract No. 433. Presented at the 34th Annual Meeting of the Society for Maternal-Fetal Medicine. February 3-8, 2014
Fried S, Kozer E, Nulman I, et al: Malformation rates in children of women with untreated epilepsy: a meta-analysis. Drug Saf 27(3):197, 2004
Geller SE, Cox SM, Callaghan WM, et al: Morbidity and mortality in pregnancy: laying the groundwork for safe motherhood. Womens Health Issues 16:176, 2006
Goldberg BB, Alvarado S, Chavez C, et al: Prevalence of periconceptional folic acid use and perceived barriers to the postgestation continuance of supplemental folic acid: survey results from a Teratogen Information Service. Birth Defects Res Part A Clin Mol Teratol 76:193, 2006
Guttler F, Lou H, Andresen J, et al: Cognitive development in offspring of untreated and preconceptionally treated maternal phenylketonuria. J Inherit Metab Dis 13:665, 1990
Hernández-Díaz S, Smith CR, Shen A, et al: Comparative safety of antiepileptic drugs during pregnancy. Neurology 78:1692, 2012
Hoeks MP, den Heijer M, Janssen MC: Adult issues in phenylketonuria. J Med 67:2, 2009
Huang L, Sauve R, Birkett N, et al: Maternal age and risk of stillbirth: a systematic review. CMAJ 178:165, 2008
Jack BW, Atrash H, Coonrod DV, et al: The clinical content of preconception care: an overview and preparation of this supplement. Am J Obstet Gynecol 199(6 Suppl 2):S266, 2008
Jack BW, Campanile C, McQuade W, et al: The negative pregnancy test. An opportunity for preconception care. Arch Fam Med 4:340, 1995
Jeha LE, Morris HH: Optimizing outcomes in pregnant women with epilepsy. Cleve Clin J Med 72:928, 2005
Jentink J, Loane MA, Dolk H, et al: Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 362(23):2185, 2010
Johnson K, Posner SF, Biermann J, et al: Recommendations to improve preconception health and health care—United States. A report of the CDC/ATSDR Preconception Care Work Group and the Select Panel on Preconception Care. MMWR Recomm Rep 55(6):1, 2006
Kim C, Ferrara A, McEwen LN, et al: Preconception care in managed care: the translating research into action for diabetes study. Am J Obstet Gynecol 192:227, 2005
Kitzmiller JL, Block JM, Brown FH, et al: Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 31(5):1060, 2008
Kitzmiller JL, Gavin LA, Gin GD, et al: Preconception care of diabetics. JAMA 265:731, 1991
Kjær D, Horvath-Puhó E, Christensen J, et al: Antiepileptic drug use, folic acid supplementation, and congenital abnormalities: a population-based case-control study. BJOG 115:98, 2008
Koch R, Hanley W, Levy H, et al: A preliminary report of the collaborative study of maternal phenylketonuria in the United States and Canada. J Inherit Metab Dis 13:641, 1990
Korteweg FJ, Bouman K, Erwich JJ, et al: Cytogenetic analysis after evaluation of 750 fetal deaths: proposal for diagnostic workup. Obstet Gynecol 111(4):865, 2008
Kouba S, Hällström T, Lindholm C, et al: Pregnancy and neonatal outcomes in women with eating disorders. Obstet Gynecol 105:255, 2005
Kuliev A, Pakhalchuk T, Verlinsky O, et al: Preimplantation genetic diagnosis for hemoglobinopathies. Hemoglobin 35(5–6):547, 2011
Leguizamón G, Igarzabal ML, Reece EA: Periconceptional care of women with diabetes mellitus. Obstet Gynecol Clin North Am 34:225, 2007
Maillot F, Cook P, Lilburn M, et al: A practical approach to maternal phenylketonuria management. J Inherit Metab Dis 30:198, 2007
Martin JA, Hamilton BE, Ventura SJ, et al. Births: final data for 2010. Natl Vital Stat Rep 61(1):1, 2012
Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2007. Natl Vital Stat Rep 58(24):1, 2010
Medical Research Council Vitamin Study Research Group: Prevention of neural tube defects: results of the Medical Research Council vitamin study. Lancet 338:131, 1991
Mills JL, Signore C: Neural tube defect rates before and after food fortification with folic acid. Birth Defects Res A Clin Mol Teratol 70(11):844, 2004
Mitchell JJ, Capua A, Clow C, et al: Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet 59:793, 1996
Moos MK: Preconceptional health promotion: progress in changing a prevention paradigm. J Perinat Neonatal Nurs 18:2, 2004
Moos MK, Bangdiwala SI, Meibohm AR, et al: The impact of a preconceptional health promotion program on intendedness of pregnancy. Am J Perinatol 13:103, 1996
Morrow JI, Hunt SJ, Russell AJ, et al: Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 80(5):506, 2009
Niccolai LM, Ethier KA, Kershaw TS, et al: Pregnant adolescents at risk: sexual behaviors and sexually transmitted disease prevalence. Am J Obstet Gynecol 188:63, 2003
O’Connor ME: Intrauterine effects in animals exposed to radiofrequency and microwave fields. Teratology 59:287, 1999
Reddy UM, Page GP, Saade GR, et al: Karyotype versus microarray testing for genetic abnormalities after stillbirth. N Engl J Med 367(23):2185, 2012
Reece EA, Homko CJ: Prepregnancy care and the prevention of fetal malformations in the pregnancy complicated by diabetes. Clin Obstet Gynecol 50:990, 2007
Robert E: Intrauterine effects of electromagnetic fields (low frequency, mid-frequency RF, and microwave): review of epidemiologic studies. Teratology 59:292, 1999
Ryan MA, Seward JF, for the Smallpox Vaccine in Pregnancy Registry Team: Pregnancy, birth, and infant health outcomes from the National Smallpox Vaccine in Pregnancy Registry, 2003–2006. Clin Infect Dis 46:S221, 2008
Sheffield JS, Butler-Koster EL, Casey BM, et al: Maternal diabetes mellitus and infant malformations. Obstet Gynecol 100:925, 2002
Silverman JG, Decker MR, Reed E, et al: Intimate partner violence victimization prior to and during pregnancy among women residing in 26 U.S. States: associations with maternal and neonatal health. Am J Obstet Gynecol 195:140, 2006
Stothard KJ, Tennant PW, Bell R, et al: Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA 301:636, 2009
Stubblefield PG, Coonrod DV, Reddy UM, et al: The clinical content of preconception care: reproductive history. Am J Obstet Gynecol 199(6 Suppl 2):S373, 2008
Thompson MW, McInnes RR, Huntington FW (eds): Genetics in Medicine, 5th ed. Philadelphia, Saunders, 1991
Tomson T, Battino D: Pregnancy and epilepsy: what should we tell our patients? J Neurol 256(6):856, 2009
Tong VT, Jones JR, Dietz PM, et al: Trends in smoking before, during, and after pregnancy-Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 31 sites, 2000–2005. MMWR 58(4):1, 2009
Tough S, Tofflemire K, Clarke M, et al: Do women change their drinking behaviors while trying to conceive? An opportunity for preconception counseling. Clin Med Res 4:97, 2006
Tripathi A, Rankin J, Aarvold J, et al: Preconception counseling in women with diabetes: a population-based study in the North of England. Diabetes Care 33(3):586, 2010
U.S. Preventative Services Task Force: Recommendation statement: folic acid for the prevention of neural tube defects. Ann Intern Med 150:629, 2009
Usta IM, Zoorob D, Abu-Musa A, et al: Obstetric outcome of teenage pregnancies compared with adult pregnancies. Acta Obstet Gynecol 87:178, 2008
Vajda FJ, Hitchcock A, Graham J, et al: Seizure control in antiepileptic drug-treated pregnancy. Epilepsia 49:172, 2008
van der Zee B, de Wert G, Steegers EA, et al: Ethical aspects of paternal preconception lifestyle modification. Am J Obstet Gynecol 209(1):11, 2013
Veiby G, Daltveit AK, Engelsen BA, et al: Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 50(9):2130, 2009
Villamor E, Cnattingius S: Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-based study. Lancet 368: 1164, 2006
Wide K, Winbladh B, Kallen B: Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide population-based register study. Acta Paediatr 93:174, 2004
Windham G, Fenster L: Environmental contaminants and pregnancy outcomes. Fertil Steril 89:e111, 2008